je.st
news
Celgene Co. (CELG) Receives New Coverage from Analysts at Standpoint Research
2016-01-18 00:05:01| Biotech - Topix.net
The firm set a "buy" rating and a $130.00 price target on the biopharmaceutical company's stock. Standpoint Research's price target points to a potential upside of 26.14% from the stock's previous close.
Tags: research
coverage
receives
analysts
Category:Biotechnology and Pharmaceuticals